Navigation Links
FOX Business Network Airing In-Depth Look at NeoStem

NEW YORK, Sept. 20 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that its CEO, Dr. Robin Smith, is appearing on WALLSTREETCAST, a national weekly television program airing on the FOX Business Network.  

The show's first segment was aired on Saturday, September 18th, and additional segments will air each upcoming Saturday at 1:30 p.m. Eastern Time through October 9th.  They may also be found online at

Dr. Smith's appearances are part of a media agreement with the Money Channel Inc. that allows the Company to tell its story to a broader audience through interviews airing each week on "Steve Crowley's American Scene," a 20-year on-air financial national radio show, and WALLSTREETCAST, which airs on the FOX Business Network during certain times of the year. Both programs feature personal finance advice, stock market-related news and advice, and include regular CEO interviews of micro-cap and small-cap companies. American Scene alone has over 3,000,000 listeners on the three-hour daily radio broadcasts and airs on hundreds of radio channels nationwide through the IRN/USA Radio Network affiliates.

"This is a great opportunity to reach out to our valued shareholders to share with them milestones we are targeting in our Company's development as we continue to work towards growing shareholder value," said Dr. Smith.

About Money Channel Inc.

The Money Channel Inc., headquartered in Coconut Creek, Florida, has operated as a media company since 2004. Its CEO, Stephen Crowley, is a former Price Waterhouse and Co. CPA-Manager, the former Money Editor of ABC's Good Morning America as well as the author of Money for Life, published by Simon & Schuster Inc. Mr. Crowley and his team have produced more than 9,000 national radio and television programs since 1982 in markets ranging from New York to San Diego and from Seattle to Miami. American Scene Radio is also co-branded with Investors Business Daily at and with founded by Jim Cramer.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: Web:

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses
2. Executive Mindshare Announces New Social Media Platform for Vertical Business Networks
3. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
4. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
5. Simbionix Relocates its Courseware Business to its Corporate Headquarters in Cleveland, Ohio
6. Bilcare AG to Acquire INEOS Global Films Business for EUR100 Million
7. Orchestrall Sponsors China Business Toolbox: Brings Focus to the How and When of China Market Access
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. THE PLANNING SHOP international Announces Oncology Business Unit
10. Sirius Genomics Announces Appointment of Senior Director of Business Development
11. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):